Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 7/2010

Open Access 01-07-2010 | Original Article

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database

Authors: G. Breart, C. Cooper, O. Meyer, C. Speirs, N. Deltour, J. Y. Reginster

Published in: Osteoporosis International | Issue 7/2010

Login to get access

Abstract

Summary

In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female patients. No greater association was shown in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic female patients.

Introduction

We explored the risk of VTE in usual practice in osteoporotic and non-osteoporotic women with and without anti-osteoporotic treatment.

Methods

A retrospective study was conducted using the GPRD in the UK. The cohorts consisted of untreated osteoporotic women (N = 11,546), osteoporotic women treated with alendronate (N = 20,084), or strontium ranelate (N = 2,408), and a sample of non-osteoporotic women (N = 115,009). Cohorts were compared using a Cox proportional hazards regression model.

Results

There was a significantly increased relative risk for VTE in untreated osteoporotic women versus non-osteoporotic women (annual incidence 5.6 and 3.2 per 1,000 patient–years, respectively; relative risk 1.75 [95% confidence interval (CI), 1.09–1.84]). Results were confirmed using adjusted models. The annual incidences of VTE in osteoporotic patients treated with strontium ranelate and alendronate were 7.0 and 7.2 per 1,000 patient–years, respectively, with no significant difference between untreated and treated patients whatever the treatment. Adjusted hazard ratios for treated versus untreated osteoporotic women were 1.09 (95% CI, 0.60–2.01) for strontium ranelate and 0.92 (95% CI, 0.63–1.33) for alendronate.

Conclusion

This study shows a greater association of VTE in osteoporotic compared to non-osteoporotic patients, but does not show any greater association in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic patients.
Literature
1.
Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, Becker RC, Goldberg RJ (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722–727CrossRefPubMed
2.
Rosendaal FR, Van Hylckama Vlieg A, Doggen CJ (2007) Venous thrombosis in the elderly. J Thromb Haemost 5(Suppl 1):310–317CrossRefPubMed
3.
Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP (2007) Venous thrombosis in the elderly: more questions than answers. Blood 110:3097–3101CrossRefPubMed
4.
5.
Guessous I, Cornuz J, Ruffieux C, Burckhardt P, Krieg MA (2008) Osteoporotic fracture risk in elderly women: estimation with quantitative heel US and clinical risk factors. Radiology 248:179–184CrossRefPubMed
6.
7.
Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRefPubMed
8.
Maclaughlin EJ, Sleeper RB, McNatty D, Raehl CL (2006) Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag 2:281–295CrossRefPubMed
9.
Roux C (2008) Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis. Rheumatology (Oxford) 47(Suppl 4):iv20–iv22CrossRef
10.
Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778CrossRefPubMed
11.
EMEA (2008) SPC: summary product characteristics (EMEA 2008)
12.
Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981–983CrossRefPubMed
13.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197CrossRefPubMed
14.
Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, DeStavola BL, Rose S, Dowell A, Wilkes HC, Darbyshire JH, Meade TW (2007) Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335:239CrossRefPubMed
15.
Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137CrossRefPubMed
16.
Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766–768CrossRefPubMed
17.
Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the general practice research database. Pharmacotherapy 23:686–689CrossRefPubMed
18.
Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD (2000) Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 49:591–596CrossRefPubMed
19.
Ray WA (2003) Evaluating medication effects outside of clinical trials: new user designs. Am J Epidemiol 158:915–920CrossRefPubMed
20.
Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L (2008) Post-marketing assessment of the safety of strontium ranelate: a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 66:689–694PubMed
21.
Farrington CP (2004) Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 22:2064–2070CrossRefPubMed
22.
Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U (2005) Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111:650–656CrossRefPubMed
23.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ III (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86:452–463PubMed
24.
Scottish Intercollegiate Guidelines Network (2002) Prophylaxis of Venous Thromboembolism: a national clinical guideline. SIGN, Edinburgh
25.
National Institute for Clinical Excellence (2007) Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in in-patients undergoing surgery. NICE Clinical guideline
26.
Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA (2007) Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 167:935–943CrossRefPubMed
27.
Fimognari FL, Repetto L, Moro L, Gianni W, Incalzi RA (2005) Age, cancer, and the risk of venous thromboembolism. Crit Rev Oncol Hematol 55:207–212CrossRefPubMed
28.
Kyrle PA, Eichinger S (2005) Venous thromboembolism in men and women. J Men’s Health & Gender 2:302–308CrossRef
29.
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5:692–699CrossRefPubMed
30.
31.
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593CrossRefPubMed
32.
Oger E (2000) Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83:657–660PubMed
33.
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340CrossRefPubMed
34.
Melton LJ III (2000) Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 15:2309–2314CrossRefPubMed
35.
Rosendaal FR (1999) Risk factors for venous thrombotic disease. Thromb Haemost 82:610–619PubMed
36.
Kwong LM (2004) Hip fracture and venous thromboembolism in the elderly. J Surg Orthop Adv 13:139–148PubMed
37.
Halil M, Cankurtaran M, Yavuz BB, Ulger Z, Piskinpasa S, Gedik A, Haznedaroglu IC, Kirazli S, Ariogul S (2007) Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 41:41–45PubMed
38.
Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755–763CrossRefPubMed
39.
40.
Diel IJ, Bergner R, Grotz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5:475–482PubMed
Metadata
Title
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database
Authors
G. Breart
C. Cooper
O. Meyer
C. Speirs
N. Deltour
J. Y. Reginster
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 7/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-009-1050-7

Other articles of this Issue 7/2010

Osteoporosis International 7/2010 Go to the issue

Review

Benefit–risk assessment of vitamin D supplementation

Original Article

Assessing interest in an osteoporosis website: a survey among women eligible for osteoporosis screening

Review

The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review

Original Article

Independent from muscle power and balance performance, a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall-related fractures in elderly men and women diagnosed with osteoporosis

Original Article

BMD T-score discriminates trochanteric fractures from unfractured controls, whereas geometry discriminates cervical fracture cases from unfractured controls of similar BMD

Original Article

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial